PRESS RELEASE published on 10/14/2025 at 18:30, 1 year 1 month ago THX PHARMA (THERANEXUS) AND EXELTIS ACHIEVE KEY MILESTONE TOWARDS THE COMMERCIALIZATION OF TX01 THX Pharma (Theranexus) and Exeltis achieve key milestone towards the commercialization of TX01 for rare neurological diseases, including Gaucher and Niemann-Pick type C. A pivotal step towards regulatory submission and global launch Commercialization Neurological Diseases Exeltis TX01 THX Pharma
BRIEF published on 09/29/2025 at 18:35, 1 year 1 month ago THX Pharma: a strategic evolution towards international expansion Growth Strategy Rare Diseases THX Pharma International Marketing Drugs TX01 And Batten-1
PRESS RELEASE published on 09/29/2025 at 18:30, 1 year 1 month ago Theranexus Becomes THX Pharma: A Strategic Evolution Toward the Commercialization of Its Medicines for Rare Diseases THX Pharma (formerly Theranexus) announces strategic focus on regulatory approval, early access, and global commercialization of new drug candidates for rare neurological diseases Regulatory Approval Commercialization Rare Neurological Diseases THX Pharma Early Access
BRIEF published on 09/25/2025 at 18:05, 1 year 1 month ago Theranexus publishes its financial results for the first half of 2025 Financial Results Cost Reduction Theranexus Batten-1 TX01
PRESS RELEASE published on 09/25/2025 at 18:00, 1 year 1 month ago THERANEXUS ANNOUNCES FIRST HALF 2025 FINANCIAL RESULTS Theranexus announces first half 2025 financial results showing a decrease in operating expenses and a net loss of €1,072 K. Focus on developing flagship asset TX01 and advancing Batten-1 Financial Results Theranexus Batten-1 Operating Expenses TX01
BRIEF published on 07/17/2025 at 18:05, 1 year 4 months ago Half-Yearly Review of the Theranexus Liquidity Contract Liquidity Contract PORTZAMPARC Financial Statement Biopharmaceuticals Theranexus
BRIEF published on 07/10/2025 at 18:05, 1 year 4 months ago Theranexus Reveals its Cash Position as of June 30, 2025 Treasury Biopharmaceutical Innovation Theranexus Batten-1 Neurological Diseases
PRESS RELEASE published on 07/10/2025 at 18:00, 1 year 4 months ago THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 JUNE 2025 Theranexus, a biopharmaceutical company, reports a cash position of €2.1M as of 30 June 2025, with upcoming funds and financial visibility through Q2 2026. CEO discusses collaborations and strategic progress. H1 2025 results expected on September 25, 2025 Cash Position Biopharmaceutical Financial Publication Theranexus Rare Neurological Diseases
BRIEF published on 05/13/2025 at 18:05, 1 year 6 months ago Theranexus and BBDF reveal promising results for Batten-1 Theranexus Batten-1 BBDF Batten Disease Visual Acuity
PRESS RELEASE published on 05/13/2025 at 18:00, 1 year 6 months ago THERANEXUS AND BEYOND BATTEN DISEASE FOUNDATION ANNOUNCE STRONG POSITIVE REAL-WORLD DATA SUPPORTING BATTEN-1 EFFICACY FOR THE TREATMENT OF BATTEN DISEASE Theranexus and BBDF announce new data supporting Batten-1 (miglustat) efficacy for CLN3 disease treatment. Results show significant preservation of visual acuity in treated patients over 12 months. Real-world analysis aligns with Phase 3 trial design Theranexus Batten-1 BBDF Visual Acuity CLN3 Disease
Published on 11/17/2026 at 15:00, 4 hours 13 minutes ago Secure Blockchain's Agentic Solutions Signs Engineering Company, Expanding Enterprise AI Into Heavy Industry
Published on 11/17/2026 at 14:45, 4 hours 28 minutes ago NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox (Monkeypox)
Published on 11/17/2026 at 14:00, 5 hours 13 minutes ago FaZe Esports, a GameSquare Company, Wins Rainbow Six Championship at Osaka Major
Published on 11/17/2026 at 14:00, 5 hours 13 minutes ago Tectonic Metals Completes Record Drill Program at Flat, Advances Five Pillars of Growth Toward Major 2027 Milestones
Published on 11/17/2026 at 18:45, 28 minutes ago HCLTech and Cohere partner to build and deliver sovereign AI
Published on 11/17/2026 at 17:54, 1 hour 18 minutes ago SKAN takes note of the Federal Criminal Court’s first-instance judgments
Published on 11/17/2026 at 18:00, 1 hour 13 minutes ago 20261117 - Accor - Accor to increase its stake in Ennismore
Published on 11/17/2026 at 17:45, 1 hour 28 minutes ago EURAZEO COMPLETES THE SALE OF ITS STAKE IN AROMA-ZONE AND ITS REINVESTMENT ALONGSIDE PARTNERS GROUP
Published on 11/17/2026 at 07:40, 11 hours 32 minutes ago SUEZ INTERNATIONAL SAS COMPLETES THE SALE OF C.10.65 MILLION SHARES OF ACEA S.P.A.
Published on 11/17/2026 at 07:30, 11 hours 43 minutes ago PR_Carrefour reaffirms its confidence in the hypermarket model, a pillar of its performance
Published on 11/17/2026 at 06:55, 12 hours 18 minutes ago Recticel Group recognised by TIME among the World's Best Companies for Sustainable Growth 2027